RESULTS	Of 417 eligible patients , 107 were randomly assigned to group A , 107 to group B , 107 to group C , and 96 to group D. Patients given pertuzumab and trastuzumab plus docetaxel ( group B ) had a significantly improved pathological complete response rate ( 49 of 107 patients ; 458 % [ 95 % CI 361-557 ] ) compared with those given trastuzumab plus docetaxel ( group A ; 31 of 107 ; 290 % [ 206-385 ] ; p = 00141 ) .\